How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

Percentage-retracement levels are yet another technical indicator useful in defining short- and long-term price trends in a security or sector. Percentage retracement levels are based upon the ...

Imagine the market is like a massive rubber band. When stretched too far in one direction, it must inevitably snap back, or retrace, before moving forward again. The challenge for the individual ...

A good sum of two good parts. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market cycle on a ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...